GH Guardant Health, Inc.

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.

Grail stock rises after a FDA advisory panel recommends approval of the biotech’s cancer blood test.

The Nasdaq hit a new high with memory giants Sandisk and Micron flashing buy signals. But financials are struggling.

Guardant Health has also earned a spot on the Investor's Business Daily Leaderboard. Earlier this month, the FDA approved Guardant360 CDx as a companion diagnostic for Etcamah from AstraZeneca in advanced or metastatic breast cancer. Guardant360 CDx is the first FDA-approved liquid biopsy CDx for longitudinal testing in breast cancer.

Ark Invest added nearly $25 million of CoreWeave as it trimmed several major AI and technology holdings

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

Guardant Health (NasdaqGS:GH) received FDA approval for its Guardant360 CDx liquid biopsy as a companion diagnostic in advanced HR-positive, HER2-negative breast cancer. The decision makes Guardant360 CDx the first FDA approved liquid biopsy companion diagnostic for longitudinal ctDNA testing in breast cancer care. The approval is supported by clinical trial data where early detection of ESR1 mutations using Guardant360 CDx informed treatment changes for patients. The Guardant360 CDx breast...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Guardant Health (NASDAQ:GH) and its peers.

Guardant Health provides services across the cancer continuum. Shares are near a buy point of 176.58 after a breakout.

Cathie Wood's ARK Invest bought another 9,037 AeroVironment shares Tuesday, extending its AVAV buying to a second consecutive session.

The S&P 500 and Nasdaq undercut key support as oil prices and Treasury yields jumped. How will bonds react to the Federal Reserve decision?

Guardant Health (GH) stands to benefit from AstraZeneca's (AZN) failed Serena-4 trial because the re

During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise my Stock Grader recommendations for 98 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly. This Week’s Ratings Changes: Upg

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. The letter can be downloaded here. Global equities rebounded sharply in Q2 2026, recovering from March lows as resilient economic data, strong corporate earnings, and continued AI investment improved investor sentiment despite inflation concerns, delayed rate cuts, and […]

Guardant Health, Inc. (NASDAQ:GH) faces a costly legal setback after a US court ordered the cancer-testing company to pay more than $245.2 million in a DNA-sequencing patent dispute. The final judgment upheld a 2023 jury verdict finding that Guardant willfully infringed two DNA-sequencing patents asserted by TwinStrand Biosciences and the University of Washington. The financial […]

Guardant Health stock has delivered very strong gains over the past three years, yet its valuation signals are split, with the intrinsic value estimate pointing to upside while broader checks suggest the shares are not a clear bargain. After a recent legal setback and a sharp multi year rise, investors are weighing how much of Guardant Health’s growth potential is already reflected in the current price. Guardant Health has returned about 327.6% over the past three years, which puts more...

In August 2026, a U.S. district court entered final judgment that Guardant Health infringed TwinStrand Biosciences and University of Washington DNA sequencing patents, ordering more than US$245.2 million in damages, accrued royalties and interest plus ongoing royalties on 11 products through March 2033. Guardant has said it will appeal and highlighted that updated versions of key tests, including Guardant Reveal and Shield, are excluded from the royalty order, while it continues to challenge...

Guardant Health (GH) is back in focus after a U.S. district court ordered the company to pay more than US$245.2 million in a patent dispute with TwinStrand Biosciences and the University of Washington. Guardant Health shares have been volatile around the legal headlines. The stock still has a 30 day share price return of 17.5% and a year to date share price return of 68.0%, while the 1 year total shareholder return of 169.17% and 3 year total shareholder return of more than 3x suggest...

A U.S. court ruled Guardant willfully infringed two core patents for DNA sequencing methods in a case brought by TwinStrand Biosciences and the University of Washington.

Veracyte's 25.3% sell-off improves the entry price as strong core test demand and earnings growth face valuation, reimbursement and launch risks.

Guardant plans to appeal the ruling, taking particular issue with a 6% ongoing royalties stipulate outlined in the court’s motion.

Guardant Health stock tumbled Monday after losing a patent battle against privately held TwinStrand Biosciences.

While traders pointed to external clinical-trial momentum as a major catalyst, Tempus's own recent guidance raise and narrowing losses provided the underlying backdrop.

During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise my Stock Grader recommendations for 161 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly. This Week’s Ratings Changes: Up

Freeport-McMoRan and Palantir scored breakouts Friday, leading five stocks near buy points from a variety of sectors.

The Nasdaq closed below its Aug. 4 follow-through day low, a highly bearish signal for the market rally. Walmart, SpaceX, CrowdStrike were big losers.

Aristotle Capital Management, LLC, an investment management company, released its “Core Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 14.69% in the second quarter of 2026, slightly trailing the 15.20% gain of the S&P 500 Index as market performance remained highly concentrated in artificial intelligence (AI)-related […]

Guardant Health (NASDAQ:GH) highlighted growth across its oncology testing, minimal residual disease, and colorectal cancer screening businesses at the Canaccord Genuity Growth Conference, with co-CEOs Helmy Eltoukhy and AmirAli Talasaz pointing to expanding adoption, new reimbursement developments,

TEM's FDA approval for xT could unlock $85 million in annual revenue from higher pricing, with bigger gains tied to xF.

TEM's faster growth, rising data demand and reimbursement potential strengthen the bull case, but high valuation and cash burn keep risks in focus.

Ian Clark exercised stock options at $50.57 and immediately liquidated the position as the precision oncology company trades near $160 per share.

Guardant Health (GH) just reported its second quarter 2026 results, with sales of US$334.98 million and a net loss of US$120.14 million, and simultaneously raised its full year 2026 revenue guidance. See our latest analysis for Guardant Health. Guardant Health’s latest earnings release, stronger revenue guidance for 2026 and the recent shelf registration filing come after a powerful run in the stock, with a 90 day share price return of 67.66% and a 1 year total shareholder return of 199.62%...

Shield screening volumes more than doubled, with UnitedHealth coverage now active.

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]

Dow Jones AI giant Microsoft stock is breaking out past a buy point following last week's earnings-fueled surge that saw the stock rally 21%.

Diagnostics company Guardant Health (NASDAQ:GH) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 44.3% year on year to $335 million. The company’s full-year revenue guidance of $1.35 billion at the midpoint came in 2.7% above analysts’ estimates. Its non-GAAP loss of $0.42 per share was 7.8% below analysts’ consensus estimates.

While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to significant downside.

July was a dreadful month for growth stocks and indexes, with things like the IBD 50 Index and the iShares MSCI USA Momentum Fund (MTUM) off well over 10%. But I still like Guardant Health Inc. (GH), which has only retreated to its 50-day line on modest volume, notes Mike Cintolo, editor of Cabot Growth Investor.

GE Aerospace and NetApp, whose enterprise data storage has made it an AI infrastructure play, lead this weekend's list of five stocks near buy points, which are showing relative strength in a tricky market. Joining GE and NTAP is oncology diagnostics firm Guardant Health. Guardant Health is part of the IBD Leaderboard portfolio of elite stocks and Viking is on the watchlist for possible inclusion.

Guardant Health (NASDAQ:GH) reported second-quarter 2026 revenue of $335 million, up 44% from a year earlier, as growth accelerated across its oncology, biopharma and data, and screening businesses. The company also raised its full-year revenue outlook, citing demand for its Guardant360 and Shield o

Moby summary of Guardant Health, Inc.'s Q2 2026 earnings call

Guardant Health Inc (GH) raises full-year guidance to $1.34-$1.36 billion as Shield volumes triple and Guardant360 Liquid CDx gains FDA approval, despite widening EBITDA losses.

Guardant Health reported past second-quarter 2026 results showing sales of US$334.98 million versus US$232.09 million a year earlier, alongside a wider net loss of US$120.14 million and loss per share of US$0.90. While revenue expanded sharply over both the quarter and first half of 2026, higher losses highlight the tension between growth investment and Guardant Health’s profitability ambitions. We’ll now examine how this strong top-line expansion, set against continued net losses, affects...

Guardant Health (GH) delivered earnings and revenue surprises of -5.00% and +6.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Diagnostics company Guardant Health (NASDAQ:GH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 44.3% year on year to $335 million. The company’s full-year revenue guidance of $1.35 billion at the midpoint came in 2.7% above analysts’ estimates. Its non-GAAP loss of $0.42 per share was 7.8% below analysts’ consensus estimates.

Guardant Health is the IBD Stock Of The Day in a thriving market for colon cancer screening tests. GH stock popped nearly 7% in extended Thursday trading. Health and biotech stocks are acting well in the current market.

Stock Market Today: The Dow Jones index rallies with the Nasdaq composite following a Fed Day tumble. Meta stock plunges on earnings.

Diagnostics company Guardant Health (NASDAQ:GH) will be announcing earnings results this Thursday after market close. Here’s what to look for.